Gendux Announces Acceptance of its ADVEXIN Marketing Authorization Application for Review by the EMEA
Gene therapy targeting inherited cancer is world's first
29-Nov-2007 -
Gendux Molecular Limited announced that its Marketing Authorization Application (MAA) for ADVEXIN® ("contusugene ladenovec" ) has been accepted for technical review by the European medicines regulatory authority (the "EMEA") for the treatment of an inherited cancer, Li-Fraumeni Syndrome (LFS). ...
diagnostic tests
gene therapies
neck cancer
+1